RecruitingNot ApplicableNCT06934473

Effects of Endogenous GIP on Postprandial Blood Pressure in Healthy Individuals

Sponsor

University Hospital, Gentofte, Copenhagen

Enrollment

16 participants

Start Date

May 21, 2025

Study Type

INTERVENTIONAL

Conditions

Bloodpressure

Summary

The present study investigates the postprandial role of endogenous glucose-dependent insulinotropic polypeptide (GIP) on cardiovascular haemodynamics, hormone responses, and hypotensive symptoms during a tilt test.

Eligibility

Min Age: 18 YearsMax Age: 40 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying GIP(1-42), GIP(3-30)NH2 / study tool, and others for people with bloodpressure. The study is currently recruiting participants at 2 locations. People eligible for this study include aged 18 Years to 40 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERGIP(3-30)NH2 / study tool

Selective antagonist of the GIPR, GIP(3-30)NH2

OTHERSaline (NaCl 0,9 %) (placebo)

Placebo (NaCl 0,9%)

OTHERGIP(1-42)

Agonist of the GIPR, GIP(1-42)

Locations(2)

Center for Clinical Metabolic Research

Copenhagen, Hellerup, Denmark

Center for Clinical Metabolic Research

Copenhagen, Hellerup, Denmark

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06934473